Back to Search
Start Over
Efficacy and Safety of Bortezomib in Patients With Plasma Cell Leukemia.
- Source :
- Cancer (0008543X); Jun2007, Vol. 109 Issue 11, p2285-2290, 6p, 3 Charts, 1 Graph
- Publication Year :
- 2007
-
Abstract
- The article discusses a study on the efficacy and safety of bortezomib in patients with plasma cell leukemia (PCL). Bortezomib is the first proteasome inhibitor approved for the treatment of advanced multiple myeloma (MM). Study subjects were patients with primary or secondary PCL who were treated with bortezomib outside of clinical trials.
Details
- Language :
- English
- ISSN :
- 0008543X
- Volume :
- 109
- Issue :
- 11
- Database :
- Complementary Index
- Journal :
- Cancer (0008543X)
- Publication Type :
- Academic Journal
- Accession number :
- 27556941
- Full Text :
- https://doi.org/10.1002/cncr.22700